Biotronik touted positive early findings from a 1st-in-man trial of its absorbable metal stent, but researchers say the device need isn't as efficient as it could be.

German medical device maker Biotronik touted early findings from a 1st-in-man study of its Dreams absorbable drug-eluting stent, with researchers reporting a mixed bag of findings for the device.
The Dreams stent proved safe at 1 year following the procedure, but wasn't up to par with some rival devices, researchers noted.
The millions of dollars in fees that medical device companies pay for FDA review aren't exempt from...
EnteroMedics expects to file for pre-market approval from the FDA this quarter for its Maestro vagal...
Natus Medical beats Wall Street's earnings forecast with a 1,000-fold profit surge on record sales,...
The U.S. Supreme Court agrees to hear Medtronic's appeal of a patent infringement loss to rival...
The New York Times lists the 10 most expensive hospitals in the United States, based on CMS data